English  |  中文
Please enter exact key words
Program Indication Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ
CAR-T Therapy
GHR106-CAR-T Cancer
RP215-CAR-T Cancer
PTG-01 Acute Lymphoblastic Leukemia (ALL)
Antibody Therapy
Anti-Scg3 Therapeutic Antibody Diabetic Retinopathy (DR)
hGHR106 Cancer
RP215 Cancer
CD3XCD20 bsAb Lymphomas
Cl3hmAb Acquired Immune Deficiency Syndrome (AIDS)
Protein Therapy
P75NEURO Neurological Diseases
P11 Type 2 Diabetes
Angiocidin Acute Myeloid Leukemia
TT-173 Surgical Bleeding and Trauma
Oncolytic Virus
RV-scFv-PDL1 Cancer
OV-FV-01 Cancer

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118
Email: info@protheragen.com

Opening Hours

Monday — Sunday: 9am — 6pm